Physician profile
Ann Monken
NPI 1043724743
$5,519.42
in general payments reported to CMS, 2019-2025
32 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $762 · 2023: $1,869 · 2024: $1,232 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,585.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,184.57 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $746.48 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $625.94 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $459.32 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $421.73 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $315.80 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $248.38 | 2023-2025 | Repatha, Repatha, Otezla |
| Axsome Therapeutics, INC. | $192.91 | 2024-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $180.68 | 2023 | Quviviq |
| Dexcom, INC. | $139.89 | 2023-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $117.23 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $115.10 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $112.64 | 2022 | |
| Exact Sciences Corporation | $87.35 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.49 | 2022-2025 | Jardiance, Ofev |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $55.42 | 2024-2025 | Azstarys |
| Astellas Pharma US INC | $52.59 | 2022-2023 | Veozah |
| Phathom Pharmaceuticals, INC. | $42.82 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $42.74 | 2025 | Rexulti |
| Abbott Laboratories | $39.84 | 2022-2023 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $34.88 | 2022-2023 | Unithroid |
| Sanofi-Aventis U.S. LLC | $33.70 | 2021-2022 | |
| Boston Scientific Corporation | $29.98 | 2025 | Watchman Flx |
| Pfizer INC. | $27.87 | 2023-2025 | |
| Ultragenyx Pharmaceutical INC. | $21.30 | 2022 | |
| Mylan Specialty L.P. | $19.64 | 2022 | |
| Lundbeck LLC | $19.44 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $17.91 | 2022 | |
| Antares Pharma, INC. | $15.82 | 2025 | Xyosted |
| Merck Sharp & Dohme LLC | $13.52 | 2022 | |
| Currax Pharmaceuticals LLC | $11.74 | 2022 | |
| Ironshore Pharmaceuticals INC. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Monken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.